Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. [electronic resource]
Producer: 19970226Description: 837-42 p. digitalISSN:- 0923-7534
- Adolescent
- Adult
- Aged
- Antineoplastic Agents, Phytogenic -- administration & dosage
- Camptothecin -- administration & dosage
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Europe
- Female
- Humans
- Infusions, Intravenous
- Irinotecan
- Male
- Middle Aged
- Neoplasms -- drug therapy
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.